Limits...
Sodium Caseinate (CasNa) Induces Mobilization of Hematopoietic Stem Cells in a BALB/c Mouse Model.

Santiago-Osorio E, Ledesma-Martínez E, Aguiñiga-Sánchez I, Poblano-Pérez I, Weiss-Steider B, Montesinos-Montesinos JJ, Mora-García Mde L - Med Sci Monit Basic Res (2015)

Bottom Line: RESULTS We found that sodium caseinate increases the number of mononuclear cells in peripheral blood with the immunophenotype of hematopoietic stem cells (0.2 to 0.5% LSK cells), allowing them to form colonies of various cell lineages in semisolid medium (p<0.05).To determine significant differences between the data, one-way ANOVA and the Tukey test were used.CONCLUSIONS Collectively these results show the utility of sodium caseinate as a mobilizer of hematopoietic stem cells and its potential clinical application in transplantation settings.

View Article: PubMed Central - PubMed

Affiliation: Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES-Zaragoza, National Autonomous University of Mexico, Mexico City, Mexico.

ABSTRACT
BACKGROUND Hematopoietic stem cells transplantation has high clinical potential against a wide variety of hematologic, metabolic, and autoimmune diseases and solid tumors. Clinically, hematopoietic stem cells derived from peripheral blood are currently used more than those obtained from sources such as bone marrow. However, mobilizing agents used in the clinic tend to fail in high rates, making the number of mobilized cells insufficient for transplantation. We investigated whether sodium caseinate induces functional mobilization of hematopoietic stem cells into peripheral blood of Balb/c mice. MATERIAL AND METHODS Using a mouse model, we administrated sodium caseinate or Plerixafor, a commercial mobilizing agent, and analyzed counts of hematopoietic stem cells in peripheral blood, and then cells were transplanted into lethally irradiated mice to restore hematopoiesis. All assays were performed at least twice. RESULTS We found that sodium caseinate increases the number of mononuclear cells in peripheral blood with the immunophenotype of hematopoietic stem cells (0.2 to 0.5% LSK cells), allowing them to form colonies of various cell lineages in semisolid medium (p<0.05). This effect is similar to that of Plerixafor, and cells transplanted into lethally irradiated mice can restore hematopoiesis at higher percentages than mononuclear cells mobilized by Plerixafor (40% vs. 20%, respectively). Further, a secondary transplant rescued a separate group of irradiated mice from death, proving definitive evidence of hematopoietic reconstitution after hematopoietic stem cells transplantation. Data are presented as mean ± standard deviation. To determine significant differences between the data, one-way ANOVA and the Tukey test were used. CONCLUSIONS Collectively these results show the utility of sodium caseinate as a mobilizer of hematopoietic stem cells and its potential clinical application in transplantation settings.

No MeSH data available.


Related in: MedlinePlus

Mononuclear cells from peripheral blood stained for HSCs (lineage negative, Sca-1+ and C-kit+) obtained from mice treated with vehicle (PBS), CasNa (0.1 g/mL), or Plerixafor (5 mg/kg).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4590580&req=5

f2-medscimonitbasicres-21-206: Mononuclear cells from peripheral blood stained for HSCs (lineage negative, Sca-1+ and C-kit+) obtained from mice treated with vehicle (PBS), CasNa (0.1 g/mL), or Plerixafor (5 mg/kg).

Mentions: To determine the ability of CasNa to mobilize HSCs into PB, Balb/c mice were inoculated i.p. with CasNa, Plerixafor, or vehicle alone (PBS) and MNCs were obtained 24 h later. The results showed that CasNa induces a significant increase in counts of MNCs, similar to that of Plerixafor, in comparison to only PBS as vehicle treatment (Figure 1). Then, LSK cells mobilized by CasNa were compared with those mobilized by Plerixafor or PBS alone, and the data demonstrated that CasNa mobilized more LSK cells than Plerixafor (0.5% and 0.3%, respectively, compared to 0.2% of PBS) (Figure 2).


Sodium Caseinate (CasNa) Induces Mobilization of Hematopoietic Stem Cells in a BALB/c Mouse Model.

Santiago-Osorio E, Ledesma-Martínez E, Aguiñiga-Sánchez I, Poblano-Pérez I, Weiss-Steider B, Montesinos-Montesinos JJ, Mora-García Mde L - Med Sci Monit Basic Res (2015)

Mononuclear cells from peripheral blood stained for HSCs (lineage negative, Sca-1+ and C-kit+) obtained from mice treated with vehicle (PBS), CasNa (0.1 g/mL), or Plerixafor (5 mg/kg).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4590580&req=5

f2-medscimonitbasicres-21-206: Mononuclear cells from peripheral blood stained for HSCs (lineage negative, Sca-1+ and C-kit+) obtained from mice treated with vehicle (PBS), CasNa (0.1 g/mL), or Plerixafor (5 mg/kg).
Mentions: To determine the ability of CasNa to mobilize HSCs into PB, Balb/c mice were inoculated i.p. with CasNa, Plerixafor, or vehicle alone (PBS) and MNCs were obtained 24 h later. The results showed that CasNa induces a significant increase in counts of MNCs, similar to that of Plerixafor, in comparison to only PBS as vehicle treatment (Figure 1). Then, LSK cells mobilized by CasNa were compared with those mobilized by Plerixafor or PBS alone, and the data demonstrated that CasNa mobilized more LSK cells than Plerixafor (0.5% and 0.3%, respectively, compared to 0.2% of PBS) (Figure 2).

Bottom Line: RESULTS We found that sodium caseinate increases the number of mononuclear cells in peripheral blood with the immunophenotype of hematopoietic stem cells (0.2 to 0.5% LSK cells), allowing them to form colonies of various cell lineages in semisolid medium (p<0.05).To determine significant differences between the data, one-way ANOVA and the Tukey test were used.CONCLUSIONS Collectively these results show the utility of sodium caseinate as a mobilizer of hematopoietic stem cells and its potential clinical application in transplantation settings.

View Article: PubMed Central - PubMed

Affiliation: Hematopoiesis and Leukemia Laboratory, Research Unit on Cell Differentiation and Cancer, FES-Zaragoza, National Autonomous University of Mexico, Mexico City, Mexico.

ABSTRACT
BACKGROUND Hematopoietic stem cells transplantation has high clinical potential against a wide variety of hematologic, metabolic, and autoimmune diseases and solid tumors. Clinically, hematopoietic stem cells derived from peripheral blood are currently used more than those obtained from sources such as bone marrow. However, mobilizing agents used in the clinic tend to fail in high rates, making the number of mobilized cells insufficient for transplantation. We investigated whether sodium caseinate induces functional mobilization of hematopoietic stem cells into peripheral blood of Balb/c mice. MATERIAL AND METHODS Using a mouse model, we administrated sodium caseinate or Plerixafor, a commercial mobilizing agent, and analyzed counts of hematopoietic stem cells in peripheral blood, and then cells were transplanted into lethally irradiated mice to restore hematopoiesis. All assays were performed at least twice. RESULTS We found that sodium caseinate increases the number of mononuclear cells in peripheral blood with the immunophenotype of hematopoietic stem cells (0.2 to 0.5% LSK cells), allowing them to form colonies of various cell lineages in semisolid medium (p<0.05). This effect is similar to that of Plerixafor, and cells transplanted into lethally irradiated mice can restore hematopoiesis at higher percentages than mononuclear cells mobilized by Plerixafor (40% vs. 20%, respectively). Further, a secondary transplant rescued a separate group of irradiated mice from death, proving definitive evidence of hematopoietic reconstitution after hematopoietic stem cells transplantation. Data are presented as mean ± standard deviation. To determine significant differences between the data, one-way ANOVA and the Tukey test were used. CONCLUSIONS Collectively these results show the utility of sodium caseinate as a mobilizer of hematopoietic stem cells and its potential clinical application in transplantation settings.

No MeSH data available.


Related in: MedlinePlus